Management of intracranial fungal infections in patients with haematological malignancies

British Journal of Haematology

Volumn 131, Issue 3, 2005, Pages 287-300

  Mattiuzzi, Gloria ^a   Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Central nervous system; Fungal infections; Haematological malignancies

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIGEN DETECTION; ASPERGILLOSIS; ASPERGILLUS; BIOPSY; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG TOLERABILITY; ENDEMIC DISEASE; HEMATOLOGIC MALIGNANCY; HISTOPLASMOSIS; HUMAN; IMMUNE DEFICIENCY; MUCORMYCOSIS; MYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROLOGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ZYGOMYCETES; BLOOD DISEASE;

ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; OPPORTUNISTIC INFECTIONS;

EID: 33644790213     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05749.x     Document Type: Review

References (111)

1. Adderson E.E. (2004) Histoplasmosis in a pediatric oncology center. Journal of Pediatrics, 144, 100 106.
2. Anstead G.M. Corcoran G. Lewis J. Berg D. Graybill J.R. (2005) Refractory coccidioidomycosis treated with posaconazole. Clinical Infectious Diseases, 40, 1770 1776.
3. Baddour L.M. Perfect J.R. Ostrosky-Zeichner L. (2005) Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clinical Infectious Diseases, 40, 409 413.
4. Bakleh M. Aksamit A.J. Tleyjeh I.M. Marshall W.F. (2005) Successful treatment of cerebral blastomycosis with voriconazole. Clinical Infectious Diseases, 40, 69 71.
5. Barchiesi F. Spreghini E. Schimizzi A.M. Maracci M. Giannini D. Carle F. Scalise G. (2004) Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrobial Agents and Chemotherapy, 48, 3312 3316.
6. Barron M.A. Lay M. Madinger N.E. (2005) Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation. Journal of Clinical Microbiology, 43, 2012 2014.
7. Black J.T. (1970) Cerebral candidiasis: case report of brain abscess secondary to Candida albicans, and review of literature. Journal of Neurology, Neurosurgery, and Psychiatry, 33, 864 870.
8. Blair J.E. Smilack J.D. Caples S.M. (2005) Coccidioidomycosis in patients with hematologic malignancies. Archives of Internal Medicine, 165, 113 117.
9. Bodey G. Bueltmann B. Duguid W. Gibbs D. Hanak H. Hotchi M. Mall G. Martino P. Meunier F. Milliken S. Naoe S. Okudaira M. Scevola D. van't Woult J. (1992) Fungal infections in cancer patients: an international autopsy survey. European Journal of Clinical Microbiology and Infectious Diseases, 11, 99 109.
10. Carrillo J.M. Jimenez E. Jimenez R. (1981) Infections in the child with acute leukemia. Boletin Medico del Hospital Infantil de Mexico, 38, 313 322.
11. Chapman S.W. Bradsher R.W. Jr. Campbell G.D. Jr. Pappas P.G. Kauffman C.A. (2000) Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clinical Infectious Diseases, 30, 679 683.
12. Chen T.L. Chen H.P. Fung C.P. Lin M.Y. Yu K.W. Liu C.Y. (2004) Clinical characteristics, treatment and prognostic factors of candidal meningitis in a teaching hospital in Taiwan. Scandinavian Journal of Infectious Diseases, 36, 124 130.
13. Chowfin A. Tight R. Mitchell S. (2000) Recurrent blastomycosis of the central nervous system: case report and review. Clinical Infectious Diseases, 30, 969 971.
14. Clemons K.V. Sobel R.A. Williams P.L. Pappagianis D. Stevens D.A. (2002) Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrobial Agents and Chemotherapy, 46, 2420 2426.
15. Cortez K.J. Walsh T.J. Bennett J.E. (2003) Successful treatment of coccidioidal meningitis with voriconazole. Clinical Infectious Diseases, 36, 1619 1622.
16. Damaj G. Ivanov V. Le Brigand B. D'incan E. Doglio M.F. Bilger K. Faucher C. Vey N. Gastaut J.A. (2004) Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Annals of Hematology, 83, 390 393.
17. Denning D.W. (1996) Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases, 23, 608 615.
18. Denning D.W. Ribaud P. Milpied N. Caillot D. Herbrecht R. Thiel E. Haas A. Ruhnke M. Lode H. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clinical Infectious Diseases, 34, 563 571.
19. Diekema D.J. Messer S.A. Hollis R.J. Jones R.N. Pfaller M.A. (2003) Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. Journal of Clinical Microbiology, 41, 3623 3626.
20. Dignani M.C. Anaissie E.J. Hester J.P. O'Brien S. Vartivarian S.E. Rex J.H. Kantarjian H. Jendiroba D.B. Lichtiger B. Andersson B.S. Freireich E.J. (1997) Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia, 11, 1621 1630.
21. Ehrmann S. Bastides F. Gissot V. Meercier E. Magro P. Bailly E. Legras A. (2005) Cerebral aspergillosis in the critically ill: two cases of successful medical treatment. Intensive Care Medicine, 31, 738 742.
22. Fernandez M. Moylett E.H. Noyola D.E. Baker C.J. (2000) Candidal meningitis in neonates: a 10-year review. Clinical Infectious Diseases, 31, 458 463.
23. Galgiani J.N. Ampel N.M. Catanzaro A. Johnson R.H. Stevens D.A. Williams P.L. (2000) Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clinical Infectious Diseases, 30, 658 661.
24. Ghannoum M.A. Okogbule-Wonodi I. Bhat N. Sanati H. (1999) Antifungal activity of voriconazole (UK-109, 496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. Journal of Chemotherapy, 11, 34 39.
25. Go J.L. Kim P.E. Ahmadi J. Seagall H.D. Zee C.S. (2000) Fungal infections of the central nervous system. Neuroimaging Clinics of North America, 10, 409 425.
26. Gonzalez G.M. Tijerina R. Najvar L.K. Bocanegra R. Luther M. Rinaldi M.G. Graybill J.R. (2001) Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrobial Agents and Chemotherapy, 45, 1854 1859.
27. Gottfredsson M. Perfect J.R. (2000) Fungal meningitis. Seminars in Neurology, 20, 307 322.
28. Greenberg R.N. Anstead G. Herbrecht R. Langston A. Marr K. Mullane K. Raad I. Schiller G. Schuster M. Van Burik J. Wingard J.R. Hare R. Corcoran G. (2003) Posaconazole (POS) Experience in the Treatment of Zygomycosis. Proceedings of the 43rd Annual Meeting on Infectious Diseases, abstract M-1757, September 14-17, Chicago, IL, 476 pp.
29. Greenberg R.N. Scott L.J. Vaughn H.H. Ribers J.A. (2004) Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Current Opinion in Infectious Diseases, 17, 517 525.
30. Groll A.H. Walsh T.J. (2001) Uncommon opportunistic fungi: new nosocomial threats. Clinical Microbiology and Infection, 7 (Suppl. 2 8 24.
31. Groll A.H. Giri N. Petraitis V. Petraitiene R. Candelario M. Bacher J.S. Piscitelli S.C. Walsh T.J. (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. Journal of Infectious Diseases, 182, 274 282.
32. Hamill R.J. Sobel J. El-Sadr W., et al. (1999) Randomized double-blind trial of Ambisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 26-29, San Francisco, CA Baddour L.M. (2003) Candida lusitaniae infections in the era of fluconazole availability. Clinical Infectious Diseases, 36, e14 e18.
33. Herbrecht R. Letscher-Bru V. Bowden R.A. Kusne S. Anaissie E.J. Graybill J.R. Noskin G.A. Oppenheim A.E. Pietrelli L.A. (2001) Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. European Journal of Clinical Microbiology and Infectious Disease, 20, 460 466.
34. Herbrecht R. Denning D.W. Patterson T.F. Bennett J.E. Greene R.E. Oestmann J.-W. Kern W.V. Marr K.A. Ribaud P. Lortholary O. Sylvester R. Rubin R.H. Wingard J.R. Stark P. Durand C. Caillot D. Thiel E. Chandrasekar P.H. Hodges M.R. Schlamm H.T. Troke P.F. de Pauw B. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. The New England Journal of Medicine, 347, 408 415.
35. Hott J.S. Horn E. Sonntag V.K.H. Coons S.W. Shetter A. (2003) Intramedullary histoplasmosis of spinal cord abscess in a nonendemic region: case report and review of the literature. Journal of Spinal Disorders and Techniques, 16, 212 215.
36. Hsue G. Napier J.T. Prince R.A. Chi J. Hospenthal D.R. (2004) Treatment of meningeal coccidioidomycosis with caspofungin. Journal of Antimicrobial Chemotherapy, 54, 292 294.
37. Isotalo P.A. Ford J.C. Veinot J.P. (2002) Miliary blastomycosis developing in an immunocompromised host with chronic lymphocytic leukaemia. Pathology, 34, 293 295.
38. Kamei K. Sano A. Kikuchi K. Makimura K. Niimi M. Suzuki K. Uehara Y. Okabe N. Nishimura K. Miyaji M. (2003) The trend of imported mycoses in Japan. Journal of Infection and Chemotherapy, 9, 16 20.
39. Kami M. Ogawa S. Kanda Y. Tanaka Y. Machida U. Matsumura T. Sakamaki H. Hirai H. (1999) Early diagnosis of central nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and enzyme-linked immunosorbent assay. British Journal of Haematology, 106, 536 537.
40. Kartsonis N.A. Saah A.J. Lipka C.J. Taylor A.F. Sable C.A. (2005) Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. Journal of Infection, 50, 196 205.
41. Kauffman C.A. (2002a) Management of histoplasmosis. Expert Opinion on Pharmacotherapy, 3, 1067 1072.
42. Kauffman C.A. (2002b) Endemic mycoses in patients with hematologic malignancies. Seminars in Respiratory Infections, 17, 106 112.
43. Kauffman C.A. (2004) Zygomycosis: reemergence of an old pathogen. Clinical Infectious Diseases, 39, 588 590.
44. Kauffman C.A. Israel K.S. Smith J.W. White A.C. Schwarz J. Brooks G.F. (1978) Histoplasmosis in immunosuppressed patients. American Journal of Medicine, 64, 923 932.
45. Kleinschmidt-DeMasters B.K. (2002) Central nervous system aspergillosis: a 20-year retrospective series. Human Pathology, 33, 116 124.
46. Kohler S. Wheat L.J. Connolly P. Schnizlein-Bick C. Durkin M. Smedema M. Goldberg J. Brizendine E. (2000) Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrobial Agents and Chemotherapy, 44, 1850 1854.
47. Kontoyiannis D.P. Wessel V.C. Bodey G.P. Rolston K.V.I. (2000) Zygomycosis in the 1990s in a tertiary-care cancer center. Clinical Infectious Diseases, 30, 851 856.
48. Kume H. Yamazaki T. Abe M. Tanuma H. Okudaira M. Okayasu I. (2003) Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathology International, 53, 744 750.
49. de Lastours V. Lefort A. Zappa M. Dufour V. Belmatoug N. Fantin B. (2003) Two cases of cerebral aspergillosis successfully treated with voriconazole. European Journal of Clinical Microbiology and Infectious Disease, 22, 297 299.
50. Leenders A.C.A.P. Reiss P. Portegies P. Clezy K. Hop W.C.J. Hoy J. Borleffs J.C.C. Allworth T. Kauffmann R.H. Jones P. Kroon F.P. Verbrugh H.A. de Marie S. (1997) Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS, 11, 1463 1471.
51. Li R.K. Ciblak M.A. Nordoff N. Pasarell L. Warnock D.W. McGinnis M.R. (2000) In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrobial Agents and Chemotherapy, 44, 1734 1736.
52. Lin S.J. Schranz J. Teutsch S.M. (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clinical Infectious Diseases, 32, 358 366.
53. Liu K.H. Wu C.J. Chou C.H. Lee H.C. Lee N.Y. Hung S.T. Ko W.C. (2004) Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. Journal of Clinical Microbiology, 42, 5950 5953.
54. Loeffler J. Hebart H. Bialek R. Hagmeyer L. Schmidt D. Serey F.P. Hartmann M. Eucker J. Einsele H. (1999) Contaminations occurring in fungal PCR assays. Journal of Clinical Microbiology, 37, 1200 1202.
55. Maertens J. Verhaegen J. Lagrou K. Van Eldere J. Boogaerts M. (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood, 97, 1604 1610.
56. Maertens J. Raad I. Petrikkos G. Boogaerts M. Selleslag D. Petersen F.B. Sable C.A. Kartsonis N.A. Ngai A. Taylor A. Patterson T.F. Denning D.W. Walsh T.J., for the Caspofungin Salvage Aspergillosis Study Group (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clinical Infectious Diseases, 39, 1563 1571.
57. Marbello L. Nosari A. Carrafiello G. Anghilieri M. Cesana C. Cafro A.M. D'Avanzo G. Morra E. (2003) Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient. Haematologica, 88, ECR05.
58. Marr B. Gross S. Cunningham C. Weiner L. (1994) Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine. Clinical Infectious Diseases, 19, 795 796.
59. Marr K.A. Carter R.A. Crippa F. Wald A. Corey L. (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical Infectious Diseases, 34, 909 917.
60. Miaux Y. Ribaud P. Williams M. Guermazi A. Gluckman E. Brocheriou C. Laval-Jeantet M. (1995) MR of cerebral aspergillosis in patients who have had bone marrow transplantation. American Journal of Neuroradiology, 16, 555 562.
61. Mikolich D.J. Kinsella L.J. Skowron G. Friedman J. Sugar A.M. (1996) Aspergillus meningitis in an immunocompetent adult successfully treated with itraconazole. Clinical Infectious Diseases, 23, 1318 1319.
62. Morrison V.A. McGlave P.B. (1993) Mucormycosis in the BMT population. Bone Marrow Transplantation, 11, 383 388.
63. Odabasi Z. Mattiuzzi G. Estey E. Kantarjian H. Saeki F. Ridge R.J. Ketchum P.A. Finkelman M.A. Rex J.H. Ostrosky-Zeichner L. (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clinical Infectious Diseases, 39, 199 205.
64. Odio C.M. Araya R. Pinto L.E. Castro C.E. Vasquez S. Alfaro B. Sàenz A. Herrera M.L. Walsh T.J. (2004) Caspofungin therapy of neonates with invasive candidiasis. Pediatric Infectious Disease Journal, 23, 1093 1097.
65. Okafuji T. Yabuuchi H. Nagatoshi Y. Hattanda Y. Fukuya T. (2003) CT and MR findings of brain aspergillosis. Computerized Medical Imaging & Graphics, 27, 489 492.
66. Ostrosky-Zeichner L. Oude Lashof A.M.L. Kullberg B.J. Rex J.H. (2003) Voriconazole salvage treatment of invasive candidiasis. European Journal of Clinical Microbiology and Infectious Disease, 22, 651 655.
67. Pagano L. Offidani M. Fianchi L. Nosari A. Candoni A. Piccardi M. Corvatta L. D'Antonio D. Girmenia C. Martino P. Del Favero A. (2004a) Mucormycosis in hematologic patients. Haematologica, 89, 207 214.
68. Pagano L. Fianchi L. Caramatti C. D'Antonio D. Melillo L. Caira M. Masini L. Todeschini G. Girmenia C. Martino B. Cinieri S. Martino P. Del Favero A. (2004b) Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. Haematologica, 89, 852 856.
69. Palanisamy A. Chao S.D. Fouts M. Kerr D. (2005) Central nervous system aspergillosis in an immunocompetent patient: cure in a hospice setting with very high-dose itraconazole. American Journal of Hospital Palliative Care, 22, 139 144.
70. Pappas P.G. Threlkeld M.G. Bedsole G.D. Cleveland K.O. Gelfand M.S. Dismukes W.E. (1993) Blastomycosis in immunocompromised patients. Medicine (Baltimore), 72, 311 325.
71. Pappas P.G. Perfect J.R. Cloud G.A. Larsen R.A. Pankey G.A. Lancaster D.J. Henderson H. Kauffman C.A. Haas D.W. Saccente M. Hamill R.J. Holloway M.S. Warren R.M. Dismukes W.E. (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clinical Infectious Diseases, 33, 690 699.
72. Pappas P.G. Rex J.H. Sobel J.D. Filler S.G. Dismukes W.E. Walsh T.J. Edwards J.E. (2004) Guidelines for treatment of candidiasis. Clinical Infectious Diseases, 38, 161 189.
73. Perea S. Patterson T.F. (2003) Endemic mycoses. In: Clinical Mycology (ed. by E.J. Anaissie M.R. McGinnin M.A. Pfaller pp. 352 369. Churchill Livingstone, Philadelphia, Pennsylvania.
74. Perfect J.R. (2005) Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clinical Infectious Diseases, 40, 401 408.
75. Perfect J.R. Cox G.M. Dodge R.K. Schell W.A. (1996) In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 40, 1910 1913.
76. Perfect J.R. Marr K.A. Walsh T.J. Greenberg R.N. DuPont B. de la Torre-Cisneros J. Just-Nubling G. Schlamm H.T. Lutsar I. Espinel-Ingroff A. Johnson E. (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clinical Infectious Diseases, 36, 1122 1131.
77. Pfaller M.A. Zhang J. Messer S.A. Brandt M.E. Hajjeh R.A. Jessup C.J. Tumberland M. Mbidde E.K. Ghannoum M.A. (1999) In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrobial Agents and Chemotherapy, 43, 169 171.
78. Proia L.A. Tenorio A.R. (2004) Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrobial Agents and Chemotherapy, 48, 2341.
79. Recht L.D. Davies S.F. Eckman M.R. Sarosi G.A. (1982) Blastomycosis in immunosuppressed patients. American Review of Respiratory Disease, 125, 359 362.
80. Rex J.H. Walsh T.J. Sobel J.D. Filler S.G. Pappas P.G. Dismukes W.E. Edwards J.E. (2000) Practice guidelines for the treatment of candidiasis. Clinical Infectious Diseases, 30, 662 678.
81. Ribaud P. Chastang C. Latge J.P. Baffroy-Lafitte L. Parquet N. Devergie A. Esperou H. Selimi F. Rocha V. Derouin F. Socie G. Gluckman E. (1999) Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clinical Infectious Diseases, 28, 322 330.
82. Rimek D. Haase G. Luck A. Casper J. Podbielski A. (2004) First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. Journal of Clinical Microbiology, 42, 481 483.
83. Rubin M.A. Carroll K.C. Cahill B.C. (2002) Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clinical Infectious Diseases, 34, 1160.
84. Saag M.S. Graybill R.J. Larsen R.A. Pappas P.G. Perfect J.R. Powderly W.G. Sobel J.D. Dismukes W.E. (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clinical Infectious Diseases, 30, 710 718.
85. Sahin B. Paydas S. Cosar E. Bicakci K. Hazar B. (1996) Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. European Journal of Clinical Microbiology and Infectious Diseases, 15, 866 869.
86. Sanchez C. Mauri E. Dalmau D. Quintana S. Aparicio A. Garau J. (1995) Treatment of cerebral aspergillosis with itraconazole: do high doses improve the prognosis? Clinical Infectious Diseases, 21, 1485 1487.
87. Sanchez-Portocarrero J. Perez-Cecilia E. Corral O. Romero-Vivas J. Picazo J.J. (2000) The central nervous system and infection by Candida species. Diagnostic Microbiology and Infectious Disease, 37, 169 179.
88. Sarma P.S. Durairaj P. Padhye A.A. (1993) Candida lusitaniae causing fatal meningitis. Postgraduate Medical Journal, 69, 878 880.
89. Scarcella A. Pasquariello M.B. Giugliano B. Vendemiia M. De Lucia A. (1998) Liposomal amphotericin B treatment for neonatal fungal infections. Pediatric Infectious Disease Journal, 17, 146 148.
90. Sepkowitz K.A. (2002) Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clinical Infectious Diseases, 34, 1098 1107.
91. Sharkey P.K. Graybill J.R. Johnson E.S. Hausrath S.G. Pollard R.B. Kolokathis A. Mildvan D. Fan-Havard P. Eng R.H. Patterson T.F. Pottage J.C. Jr. Simberkoff M.S. Wolf J. Meyer R.D. Gupta R. Lee L.W. Gordon D.S. (1996) Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases, 22, 315 321.
92. Shih C.C. Chen Y.C. Chang S.C. Luh K.T. Hsieh W.C. (2000) Cryptococcal meningitis in non-HIV-infected patients. QJM: Monthly Journal of the Association of Physicians, 93, 245 251.
93. Stevens D.A. Kan V.L. Judson M.A. Morrision V.A. Dummer S. Denning D.W. Bennett J.E. Walsh T.J. Patterson T.F. Pankey G.A. (2000) Practice guidelines for diseases caused by Aspergillus. Clinical Infectious Diseases, 30, 696 709.
94. Stevens D.A. Rendon V. Gaona A. Catanzaro L. Pedicone G. Corcoran J. Graybill R. (2004) Posaconazole therapy for chronic refractory Coccidioidomycosis. Proceedings of the 44th Annual Meeting on Infectious Diseases, abstract M-663, October 30-November 2, Washington, DC, 410 pp.
95. Sugar A.M. Liu X.P. (1996) In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrobial Agents and Chemotherapy, 40, 1314 1316.
96. Sugar A.M. Liu X.P. (2001) Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrobial Agents and Chemotherapy, 45, 601 604.
97. Sun Q.N. Fothergill A.W. McCarthy D.I. Rinaldi M.G. Graybill J.R. (2002) In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrobial Agents and Chemotherapy, 46, 1581 1582.
98. Tietz H.J. Martin H. Koch S. (2001) Incidence of endomycoses in autopsy material. Mycoses, 44, 450 454.
99. Troke P.F. Schwartz S. Ruhnke M. Ribaud P. Corey L. Driscoll T. Fätkenheuer G. Schuler U. Thiel E. Dodell B. Lutsar I. (2003) Voriconazole (VRC) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract M-1755), Chicago, IL, 476 pp.
100. Tweddle D.A. Graham J.C. Shankland G.S. Kernahan J. (1998) Cerebral candidiasis in a child 1 year after leukaemia. British Journal of Haematology, 103, 795 797.
101. Uchida K. Yokota N. Yamaguchi H. (2001) In vitro antifungal activity of posaconazole against various pathogenic fungi. International Journal of Antimicrobial Agents, 18, 167 172.
102. Verduyn Lunel F.M. Voss A. Kuijper E.J. Gelinck L.B. Hoogerbrugge P.M. Liem K.L. Kullberg B.J. Verweij P.E. (2004) Detection of the Candida antigen mannan in cerebrospinal fluid specimens from patients suspected of having Candida meningitis. Journal of Clinical Microbiology, 42, 867 870.
103. Verweij P.E. Brinkman K. Kremer H.P. Kullberg B.J. Meis J.F. (1999) Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. Journal of Clinical Microbiology, 37, 1186 1189.
104. Verweij P.E. Figueroa J. Van Burik J. Holdom M.D. Dei-Cas E. Gomez B.L. Mendes-Giannini M.J. (2000) Clinical applications of non-culture based methods for the diagnosis and management of opportunistic and endemic mycoses. Medical Mycology, 38, 161 171.
105. Vincent T. Galgiani J.N. Huppert M. Salkin D. (1993) The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clinical Infectious Diseases, 16, 247 254.
106. Voice R.A. Bradley S.F. Sangeorzan J.A. Kauffman C.A. (1994) Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clinical Infectious Diseases, 19, 60 66.
107. Walsh T.J. Hier D.B. Caplan L.R. (1985) Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Annals of Neurology, 18, 574 582.
108. Walsh T.J. Goodman J.L. Pappas P. Bekersky I. Buell D.N. Roden M. Barrett J. Anaissie E.J. (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrobial Agents and Chemotherapy, 45, 3487 3496.
109. Wheat L.J. Batteiger B.E. Sathapatayavongs B. (1990) Histoplasma capsulatum infections of the central nervous system. A clinical review. Medicine (Baltimore), 69, 244 260.
110. Wheat J. Sarosi G. McKinsey D. Hamill R. Bradsher R. Johnson P. Loyd J. Kauffman C. (2000) Practice guidelines for the management of patients with histoplasmosis. Clinical Infectious Diseases, 30, 688 695.
111. Williams P.L. Johnson R. Pappagianis D. Einstein H. Slager U. Koster F.T. Eron J.J. Morrison J. Aguet J. River M.E. (1992) Vasculitic and encephalitic complications associated with Coccidioides immitis infection of the central nervous system in humans: report of 10 cases and review. Clinical Infectious Diseases, 14, 673 682.